CA3119580A1 - Crosslinked artificial nucleic acid alna - Google Patents
Crosslinked artificial nucleic acid alna Download PDFInfo
- Publication number
- CA3119580A1 CA3119580A1 CA3119580A CA3119580A CA3119580A1 CA 3119580 A1 CA3119580 A1 CA 3119580A1 CA 3119580 A CA3119580 A CA 3119580A CA 3119580 A CA3119580 A CA 3119580A CA 3119580 A1 CA3119580 A1 CA 3119580A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituents
- optionally substituted
- methyl
- oxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018212424 | 2018-11-12 | ||
| JP2018-212424 | 2018-11-12 | ||
| PCT/JP2019/044182 WO2020100826A1 (ja) | 2018-11-12 | 2019-11-11 | 架橋型人工核酸ａｌｎａ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3119580A1 true CA3119580A1 (en) | 2020-05-22 |
Family
ID=70731902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3119580A Pending CA3119580A1 (en) | 2018-11-12 | 2019-11-11 | Crosslinked artificial nucleic acid alna |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12338265B2 (https=) |
| EP (3) | EP4275690A3 (https=) |
| JP (1) | JP7356448B2 (https=) |
| KR (1) | KR102886120B1 (https=) |
| CN (4) | CN119119156A (https=) |
| AU (1) | AU2019381386C1 (https=) |
| BR (1) | BR112021009168A2 (https=) |
| CA (1) | CA3119580A1 (https=) |
| IL (2) | IL283103B2 (https=) |
| MX (1) | MX2021005537A (https=) |
| MY (1) | MY208522A (https=) |
| PH (1) | PH12021551082A1 (https=) |
| SG (1) | SG11202104901VA (https=) |
| WO (1) | WO2020100826A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7776420B2 (ja) * | 2020-05-12 | 2025-11-26 | 田辺三菱製薬株式会社 | Ａｔａｘｉｎ ３発現を調節するための化合物、方法及び医薬組成物 |
| JP2023130528A (ja) * | 2020-06-24 | 2023-09-21 | 田辺三菱製薬株式会社 | Ｐｌｐ１発現を調節するための化合物、方法及び医薬組成物 |
| JPWO2022014703A1 (https=) | 2020-07-17 | 2022-01-20 | ||
| WO2024101446A1 (ja) | 2022-11-10 | 2024-05-16 | ルクサナバイオテク株式会社 | 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法 |
| CN120418261A (zh) | 2022-12-21 | 2025-08-01 | 田边三菱制药株式会社 | 制造中间体的制造方法、该制造中间体及使用其的桥连型人工核酸中间体的制造方法 |
| WO2025206092A1 (ja) * | 2024-03-27 | 2025-10-02 | 田辺三菱製薬株式会社 | Ｍｙｏｒｅｇｕｌｉｎ発現を調節するための化合物及び医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4236812B2 (ja) * | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| AU9393798A (en) | 1997-09-17 | 1999-04-05 | Affymetrix, Inc. | Genetic compositions and methods |
| WO2007145593A1 (en) * | 2006-06-15 | 2007-12-21 | Jyoti Chattopadhyaya | Conformationally constrained 2' -n,4' -c-ethylene-bridged thymidine (aza-ena-t) |
| EP2580228B1 (en) * | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| BR112014001075A2 (pt) | 2011-07-19 | 2016-11-29 | Univ Idaho | sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit |
| KR101707437B1 (ko) * | 2012-09-21 | 2017-02-16 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드 |
| WO2014124952A1 (en) | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| WO2016128583A2 (en) | 2015-02-15 | 2016-08-18 | Ribo Task Aps | Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| WO2020203880A1 (ja) | 2019-03-29 | 2020-10-08 | 田辺三菱製薬株式会社 | Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物 |
-
2019
- 2019-11-11 US US17/292,963 patent/US12338265B2/en active Active
- 2019-11-11 CN CN202411221568.6A patent/CN119119156A/zh active Pending
- 2019-11-11 AU AU2019381386A patent/AU2019381386C1/en active Active
- 2019-11-11 IL IL283103A patent/IL283103B2/en unknown
- 2019-11-11 CA CA3119580A patent/CA3119580A1/en active Pending
- 2019-11-11 CN CN202410087638.7A patent/CN117964674A/zh active Pending
- 2019-11-11 MY MYPI2021002591A patent/MY208522A/en unknown
- 2019-11-11 EP EP23191049.8A patent/EP4275690A3/en active Pending
- 2019-11-11 CN CN202410087635.3A patent/CN117964673A/zh active Pending
- 2019-11-11 MX MX2021005537A patent/MX2021005537A/es unknown
- 2019-11-11 SG SG11202104901VA patent/SG11202104901VA/en unknown
- 2019-11-11 CN CN201980074116.0A patent/CN112996522B/zh active Active
- 2019-11-11 EP EP19885739.3A patent/EP3881851A4/en active Pending
- 2019-11-11 BR BR112021009168-8A patent/BR112021009168A2/pt unknown
- 2019-11-11 JP JP2020555685A patent/JP7356448B2/ja active Active
- 2019-11-11 WO PCT/JP2019/044182 patent/WO2020100826A1/ja not_active Ceased
- 2019-11-11 KR KR1020217017322A patent/KR102886120B1/ko active Active
- 2019-11-11 IL IL316158A patent/IL316158B1/en unknown
- 2019-11-11 EP EP23191048.0A patent/EP4275689A3/en active Pending
-
2021
- 2021-05-11 PH PH12021551082A patent/PH12021551082A1/en unknown
-
2025
- 2025-05-16 US US19/210,578 patent/US20250340584A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021551082A1 (en) | 2021-11-22 |
| IL283103A (en) | 2021-06-30 |
| WO2020100826A1 (ja) | 2020-05-22 |
| JPWO2020100826A1 (ja) | 2021-09-30 |
| KR102886120B1 (ko) | 2025-11-14 |
| KR20210090659A (ko) | 2021-07-20 |
| EP3881851A4 (en) | 2023-02-15 |
| BR112021009168A2 (pt) | 2021-08-17 |
| CN112996522A (zh) | 2021-06-18 |
| MY208522A (en) | 2025-05-14 |
| US20250340584A1 (en) | 2025-11-06 |
| CN112996522B (zh) | 2024-09-20 |
| IL316158B1 (en) | 2026-04-01 |
| CN117964673A (zh) | 2024-05-03 |
| MX2021005537A (es) | 2021-09-10 |
| CN117964674A (zh) | 2024-05-03 |
| EP4275690A2 (en) | 2023-11-15 |
| AU2019381386A1 (en) | 2021-06-17 |
| EP4275690A3 (en) | 2023-11-22 |
| SG11202104901VA (en) | 2021-06-29 |
| AU2019381386C1 (en) | 2025-11-27 |
| AU2019381386B2 (en) | 2025-06-26 |
| IL283103B2 (en) | 2025-04-01 |
| US12338265B2 (en) | 2025-06-24 |
| EP4275689A2 (en) | 2023-11-15 |
| EP4275689A3 (en) | 2023-11-22 |
| JP7356448B2 (ja) | 2023-10-04 |
| IL316158A (en) | 2024-12-01 |
| US20220002336A1 (en) | 2022-01-06 |
| IL283103B1 (en) | 2024-12-01 |
| CN119119156A (zh) | 2024-12-13 |
| EP3881851A1 (en) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3119580A1 (en) | Crosslinked artificial nucleic acid alna | |
| JP2023075302A (ja) | 架橋型核酸ＧｕＮＡ、その製造方法および中間体化合物 | |
| CN118063533B (zh) | 修饰的核苷酸化合物、其寡聚核苷酸及其应用 | |
| JPWO2018181428A1 (ja) | 核酸医薬及び多分岐脂質の複合体 | |
| TW202237848A (zh) | 靶向ｔａｕ之寡核苷酸缺口體 | |
| AU2020267486B2 (en) | Modified cyclic dinucleoside compounds as STING modulators | |
| RU2820226C2 (ru) | Сшитая искусственная нуклеиновая кислота alna | |
| HK40103028A (en) | Crosslinked artificial nucleic acid alna | |
| HK40103029A (en) | Crosslinked artificial nucleic acid alna | |
| HK40061613A (en) | Crosslinked artificial nucleic acid alna | |
| CA2999199A1 (en) | Crosslinked nucleic acid guna, method for producing same, and intermediate compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220817 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240909 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240909 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241029 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250714 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251008 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251008 |